News Releases

Date	Title and Summary	View
Apr 16, 2021	Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting
Apr 12, 2021	Johnson & Johnson to Participate in the BofA Securities Virtual 2021 Healthcare Conference
Mar 29, 2021	Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 Vaccine Candidate
Mar 26, 2021	Janssen Receives Positive CHMP Opinion for PONVORY™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features
Mar 19, 2021	Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
Mar 16, 2021	New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
Mar 12, 2021	Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
Mar 11, 2021	Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
Mar 11, 2021	Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
Mar 10, 2021	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results